Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objective: No study examined the association of the oxidative balance score (OBS) with mortality in patients with arthritis. This study examined the association between OBS and all-cause and cardiovascular mortality in patients with arthritis.
Methods: From NHANES, 11,754 patients with arthritis were included. The patients were from the 1999-2018 period. The OBS was calculated using 16 nutrients and four lifestyle factors. The outcomes were all-cause mortality and cardiovascular diseases (CVD) mortality. CVD mortality was defined as death from ICD-10 codes I00-I09, I11, I13, and I20-I51. The Kaplan-Meier analysis and log-rank test were used to depict the survival rate disparities among different groups of patients. The associations of various variables with all-cause mortality and CVD mortality were evaluated using three multivariable Cox regression models.
Results: The cohort study included 11,754 patients with arthritis, with a mean (SE) age 59.41 (0.22) years and 4,871 men (weighted, 41.44%). Kaplan-Meier analysis showed lower OBS scores are associated with higher overall mortality and CVD mortality (p < 0.001). Multivariable Cox proportional hazard regression model analysis showed that, after adjusting for multiple confounders, the highest OBS quartile had 30% lower all-cause mortality risk (HR = 0.70, 95%CI: 0.58-0.85) and CVD mortality (HR = 0.70, 95%CI: 0.58-0.85, P < 0.001), compared with the lowest quartile. Restricted cubic spline (RCS) curves showed a negative linear association between OBS and both mortality types (p < 0.001). Similar trends were observed for the lifestyle OBS, while dietary OBS showed no independent inverse association on both mortality types in fully adjusted models.
Conclusion: Higher OBS might be associated with lower all-cause and cardiovascular mortality in patients with arthritis, highlighting the importance of adhering to an antioxidant lifestyle in patients with arthritis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330014 | PMC |
| http://dx.doi.org/10.1186/s12889-025-24041-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expanded senescent CD8 T-cells in IMID patients are associated with distinct inflammatory cytokines.
Clin Exp Immunol
September 2025
Rheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA , FHU CARE, Le Kremlin Bicêtre, France.
Introduction: Immunosenescence remodels immune functions and was first described with aging. It is present in 25% of cancer patients but has also been described in patients with Immune-mediated inflammatory diseases (IMIDs). This study aims at quantifying cells exhibiting a phenotype of senescence in CD4+ (T4sen) and CD8+ (T8sen) T cells, analyzing its potential drivers and the effect of anti-TNF treatment in a prospective cohort of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and Sjögren disease (SjD).
View Article and Find Full Text PDFChallenges, benefits, and strategies for delivering pregnancy care to people with disabilities: A qualitative study of service providers and decision-makers in Ontario, Canada.
J Health Serv Res Policy
September 2025
Department of Health and Society, University of Toronto Scarborough, Toronto, ON, Canada.
ObjectivesTo (1) understand the challenges and benefits of providing pregnancy care to people with disabilities and (2) identify strategies to address challenges, from the perspectives of health care and social service providers and decision-makers.MethodsWe undertook a qualitative descriptive study in Ontario, Canada, of 31 health care and social service providers and decision-makers. Participants completed semi-structured interviews about their education, training, and clinical or administrative experience working with pregnant and/or parenting people with physical, sensory, and intellectual or developmental disabilities, including challenges and benefits in pregnancy care provision, programming, and policies, as well as their recommendations to improve care.
View Article and Find Full Text PDFOmics-driven insights into the molecular pathways driving osteoarthritis pathogenesis.
Connect Tissue Res
September 2025
Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland.
Osteoarthritis (OA) is a multifactorial, mechano-inflammatory joint disorder characterized by cartilage degradation, synovial inflammation, and subchondral bone remodeling. Despite its high prevalence and significant impact on quality of life, no disease-modifying treatments have been approved. In many other disease areas, advanced omics technologies are impacting the development of advanced therapies.
View Article and Find Full Text PDFFactors influencing delayed attainment of low disease activity in rheumatoid arthritis patients continuing targeted therapy.
Korean J Intern Med
September 2025
Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Background/aims: To identify factors associated with achieving low disease activity (LDA) after 48 weeks of targeted therapy in patients with rheumatoid arthritis (RA) despite not meeting treat-to-target (T2T) criteria at week 24.
Methods: Data were collected from a multicenter, prospective observational cohort of Korea patients with RA receiving targeted therapy between April 2020 and July 2023. Patients who continued their initial targeted therapy despite not achieving LDA at week 24 were assigned to the LDA and non-LDA groups at week 48.
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.